Congressional Problem Solvers Caucus Endorses RESULTS Act
A bipartisan congressional caucus recently announced its endorsement of the Reforming and Enhancing Sustainable Updates to Laboratory Testing...
The Centers for Medicare & Medicaid Services (CMS) is expanding Medicare coverage for genetic testing through the MolDX program administered by Palmetto GBA.
CMS announced two new local coverage determinations (LCDs) to cover diagnostic tests used to evaluate and manage care for patients suspected of having hereditary transthyretin amyloidosis:
- Genetic Testing for Heritable Thoracic Aortic Disease (L39933)
- Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (L39935)
The LCDs will take effect Aug. 17 in 23 states.
Source:
https://www.cap.org/advocacy/latest-news-and-practice-data/july-8-2025
Senate HELP Committee Votes to Advance Price Transparency Legislation
On July 22, the Senate Health, Education, Labor, and Pensions (HELP) Committee voted to advance the Patients Deserve Price Tags Act (S.2355) by a...
The Rise of CLIA-Related Rejections: What Labs Should Review
Since CMS transitioned CLIA certification to a paperless system in March, TELCOR has noticed an increase in CLIA-related rejections and denials from...